ADVFN - Advanced Financial Network.
HOME» NYSE » F » FRX Stock Price » FRX Stock News

Forest Labs Share News

 Forest Laboratories, Inc. Stock Price
FRX Stock Price
 Forest Laboratories, Inc. Stock Chart
FRX Stock Chart
 Forest Laboratories, Inc. Stock News
FRX Stock News
 Forest Laboratories, Inc. Company Information
FRX Company Information
 Forest Laboratories, Inc. Stock Trades
FRX Stock Trades

Forest Labs, Janssen Sue Several Drug Makers Over Bystolic

DOW JONES NEWSWIRES Forest Laboratories Inc. (FRX) and Johnson & Johnson's (JNJ) Janssen Pharmaceutica NV sued several drug makers over plans to market generic versions of Forest's Bystolic hypertension drug, citing an existing patent. The lawsuit before the U.S. District Court in Delaware names units of Amerigen Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd. (532296.BY), Hetero USA Inc., Torrent Pharmaceuticals Ltd. (500420.BY) and Watson Pharmaceuticals Inc. (WPI) as defendants. The two drug makers also sued Alkem Laboratories Ltd. and Indchemie Health Specialties Pvt. Ltd in Chicago's U.S. district court. Forest's patent on the blood-pressure medication expires in December 2021 after patent-term extension. Shares of Forest were up 10 cents at $33.80 mid-Wednesday, in line with the broader market. Johnson & Johnson was off 21 cents at $65.12. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909;

Stock News for Forest Labs (FRX)
04/05/201509:52:02Can This Pharma Go From Good to Great?

Forest Labs and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations